<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00095706</url>
  </required_header>
  <id_info>
    <org_study_id>TORI B-03</org_study_id>
    <secondary_id>Western IRB #20041069</secondary_id>
    <secondary_id>UCLA IRB #01-09-030</secondary_id>
    <nct_id>NCT00095706</nct_id>
    <nct_alias>NCT00093535</nct_alias>
  </id_info>
  <brief_title>Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)</brief_title>
  <official_title>Phase I/II Combined Biological Therapy of Breast Cancer Using Monoclonal Antibodies Directed Against HER2/Neu Proto-Oncogene and Vascular Endothelial Growth Factor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Translational Oncology Research International</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Translational Oncology Research International</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of combined treatment
      with trastuzumab (Herceptin) and bevacizumab (anti-VEGF antibody) in patients with
      HER2-positive metastatic breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Based on preclinical experiments conducted in our laboratories, we hypothesize that the
      aggressive behavior of HER2-overexpressing breast cancers is due in part to increased
      angiogenesis resulting from HER2-induced increases in vascular endothelial growth factor
      (VEGF) expression. In vivo experiments suggest that combined blockade of the HER2 receptor
      and VEGF results in superior anti-tumor efficacy compared with either treatment alone.

      The current clinical trial, for which the phase I portion has been completed, will examine
      the efficacy and safety of trastuzumab (Herceptin) and bevacizumab (anti-VEGF antibody) in
      the treatment of HER2-overexpressing metastatic breast cancer.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To establish the maximum tolerated dose (MTD) or recommended phase II dose of rhuMAb VEGF (bevacizumab) administered intravenously every 14 days to patients with HER2-amplified relapsed or metastatic breast cancer receiving concomitant Herceptin therapy</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the clinical safety and toxicities of rhuMAb VEGF when administered in combination with Herceptin</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetics of rhuMAb VEGF and Herceptin given in combination</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of rhuMAb VEGF plus Herceptin in terms of clinical activity when administered as an intravenous infusion, in patients with previously untreated metastatic or relapsed breast cancer</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab (drug), Herceptin (drug)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metastatic or relapsed locally advanced breast cancer

          -  HER2-positive by FISH

          -  No prior chemotherapy for metastatic disease

          -  ECOG performance status 0-2

          -  Normal left ventricular ejection fraction

          -  Bidimensionally measurable disease

          -  Oxygen saturation &gt; 90% on room air

        Exclusion Criteria:

          -  Other invasive malignancy within 5 years

          -  More than 3 different metastatic sites

          -  &gt;50% liver involvement by metastasis

          -  Newly diagnosed untreated Stage IIIB breast cancer

          -  Prior chemotherapy for metastatic disease

          -  Clinically significant cardiovascular disease

          -  History or evidence of CNS disease

          -  Major surgery within 28 days prior to day 0

          -  Current or recent use of parenteral anticoagulants

          -  WBC &lt; 3,000/uL

          -  Platelet count &lt; 75,000/uL

          -  Hemoglobin &lt; 9.0 g/dL

          -  Total Bilirubin &gt; 2.0 mg/dL

          -  AST or ALT &gt; 5 time upper limit of normal for subjects with documented liver
             metastases; &gt; 2.5 times upper limit of normal for subjects without evidence of liver
             metastases

          -  Proteinuria (&gt; 1g protein/24 hours at baseline)

          -  Prior therapy with Herceptin or rhuMAb VEGF (bevacizumab)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark D Pegram, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fairooz Kabbinavar, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Chief Medical Officer, TORI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central Hematology Oncology Medical Group, Inc.</name>
      <address>
        <city>Alhambra</city>
        <state>California</state>
        <zip>91801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Blood and Cancer Center</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia K. Crosson Cancer Center</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Shores Medical Group</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Valley Hematology/Oncology Medical Group</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ventura County Hematology-Oncology Specialists</name>
      <address>
        <city>Oxnard</city>
        <state>California</state>
        <zip>93030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilshire Oncology Medical Group, Inc.</name>
      <address>
        <city>Pomona</city>
        <state>California</state>
        <zip>91767</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Associates Medical Group, Inc.</name>
      <address>
        <city>Redondo Beach</city>
        <state>California</state>
        <zip>90277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sansum Santa Barbara Medical Foundation Clinic</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Barbara Hematology Oncology Medical Group, Inc.</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Diego Cancer Center</name>
      <address>
        <city>Vista</city>
        <state>California</state>
        <zip>92081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute of Florida, P.A.</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Georgia Cancer Care, LLC</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suburban Hematology-Oncology Associates, P.A.</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Georgia Oncology Centers, P.C.</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Associates of Central Illinois, P.C.</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2004</study_first_submitted>
  <study_first_submitted_qc>November 5, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2004</study_first_posted>
  <last_update_submitted>September 23, 2015</last_update_submitted>
  <last_update_submitted_qc>September 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2015</last_update_posted>
  <responsible_party>
    <name_title>Sara Hurvitz</name_title>
    <organization>University of California, Los Angeles</organization>
  </responsible_party>
  <keyword>Metastatic breast cancer</keyword>
  <keyword>HER2</keyword>
  <keyword>Trastuzumab</keyword>
  <keyword>Herceptin</keyword>
  <keyword>VEGF</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Avastin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Endothelial Growth Factors</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

